Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas

globenewswire.com
GSK Mentioned for potential approval of depemokimab in asthma and sinusitis, indicating a pipeline event but not a direct stock performance prediction. RGNX Mentioned for potential approval of clemidsogene lanparvovec in Hunter syndrome, indicating a pipeline event but not a direct stock performance prediction. OMER Mentioned for potential approval of narsoplimab in thrombotic microangiopathy, indicating a pipeline event but not a direct stock performance prediction. XENE Mentioned for ongoing clinical trials with azetukalner for focal onset seizures, indicating pipeline activity but not a direct stock performance prediction. NMRA Mentioned for ongoing clinical trials with navacaprant for major depressive disorder, indicating pipeline activity but not a direct stock performance prediction.

Dublin, Jan. 20, 2026 (GLOBE NEWSWIRE) -- The "Catalyst Monitor: Q1 2026 Outlook" report has been added to ResearchAndMarkets.com's offering.

This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q1 2026.

The report delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, top-line results, regulatory filings, PDUFA dates, and expected approvals. The report covers 13 significant catalyst events that are expected to occur in Q1 2026.

Some of the catalysts covered in the report, include approval decisions for GSK's depemokimab in asthma and sinusitis, Regenxbio's clemidsogene lanparvovec in Hunter syndrome, Omeros' narsoplimab in thrombotic microangiopathy, and more.

Additionally, experts also discuss the ongoing clinical trials with Xenon Pharmaceuticals' azetukalner for focal onset seizures, Cerevel's tavapadon for Parkinson's disease, Neumora's navacaprant for major depressive disorder (MDD), and more.

Report Scope

Reasons to Buy

Key Topics Covered:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/h22wta

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.